Literature DB >> 9653045

Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression.

W A Paxton1, S Kang.   

Abstract

It is now well established that an array of CC and CXC chemokine receptors, in association with the CD4 molecule, can interact with the HIV-1 gp120 protein to facilitate viral fusion. A 32bp deletion in the CC chemokine receptor CCR5, the major M-tropic viral co-receptor, provides considerable protection against HIV-1 transmission and has been associated with a delay in disease progression. The effects of the Delta32 allele appear to be mediated through the phenotype of CCR5 expression as opposed to genotype. Here we discuss the potential effects that the Delta32 allele and other polymorphisms in the chemokine receptor repertoire may have on both HIV-1 transmission and disease progression. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653045     DOI: 10.1006/smim.1998.0132

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  15 in total

1.  Distribution of CCR-5Δ32, CCR2-64I, and SDF-1-3'A alleles among Jordanians.

Authors:  Omar F Khabour; Laila J Abu-Haweleh; Karem H Alzoubi
Journal:  AIDS Res Hum Retroviruses       Date:  2012-07-31       Impact factor: 2.205

2.  Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection.

Authors:  Leia H Wren; Amy W Chung; Gamze Isitman; Anthony D Kelleher; Matthew S Parsons; Janaki Amin; David A Cooper; Ivan Stratov; Marjon Navis; Stephen J Kent
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

Review 3.  Genetic variation and HIV-associated neurologic disease.

Authors:  Satinder Dahiya; Bryan P Irish; Michael R Nonnemacher; Brian Wigdahl
Journal:  Adv Virus Res       Date:  2013       Impact factor: 9.937

4.  Expression of Nef downregulates CXCR4, the major coreceptor of human immunodeficiency virus, from the surfaces of target cells and thereby enhances resistance to superinfection.

Authors:  Stephanie Venzke; Nico Michel; Ina Allespach; Oliver T Fackler; Oliver T Keppler
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

5.  Characteristics of a pathogenic molecular clone of an end-stage serum-derived variant of simian immunodeficiency virus (SIV(F359)).

Authors:  L Holterman; R Dubbes; J Mullins; G Learn; H Niphuis; W Koornstra; G Koopman; E M Kuhn; A Wade-Evans; B Rosenwirth; J Haaijman; J Heeney
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains.

Authors:  Samantha H Johnston; Michael A Lobritz; Sandra Nguyen; Kara Lassen; Shirley Delair; Filippo Posta; Yvonne J Bryson; Eric J Arts; Tom Chou; Benhur Lee
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

7.  Chemokine receptor 5 Δ32 polymorphism and systemic lupus erythematosus, vasculitis, and primary Sjogren's syndrome. Meta-analysis of possible associations.

Authors:  Y H Lee; J-H Kim; G G Song
Journal:  Z Rheumatol       Date:  2014-11       Impact factor: 1.372

8.  CCR5: From Natural Resistance to a New Anti-HIV Strategy.

Authors:  Lucia Lopalco
Journal:  Viruses       Date:  2010-02-05       Impact factor: 5.818

9.  Comparative expression profile of miRNA and mRNA in primary peripheral blood mononuclear cells infected with human immunodeficiency virus (HIV-1).

Authors:  Ankit Gupta; Pruthvi Nagilla; Hai-Son Le; Coulton Bunney; Courtney Zych; Anbupalam Thalamuthu; Ziv Bar-Joseph; Sinnakaruppan Mathavan; Velpandi Ayyavoo
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

10.  MicroRNA regulation and its effects on cellular transcriptome in human immunodeficiency virus-1 (HIV-1) infected individuals with distinct viral load and CD4 cell counts.

Authors:  Karolina Duskova; Pruthvi Nagilla; Hai-Son Le; Priyadarshini Iyer; Anbupalam Thalamuthu; Jeremy Martinson; Ziv Bar-Joseph; William Buchanan; Charles Rinaldo; Velpandi Ayyavoo
Journal:  BMC Infect Dis       Date:  2013-05-30       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.